Clinical Trial Update: Open Label Study of Subcutaneous Immunoglobulin (SCIg) in Myasthenia Gravis [Phase 2]

View source ↗

Summary

Open-label Phase 2 trial evaluating subcutaneous immunoglobulin in patients with Myasthenia Gravis has completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myasthenia Gravis

Drugs mentioned

• Subcutaneous immunoglobulin (immunoglobulin)

Snippet

Sponsor: Mazen Dimachkie, MD | Conditions: Myasthenia Gravis | Phase 2 | Status: COMPLETED | Results posted: 2019-12-13